Mumbai, July 22, 2025 – Godavari Biorefineries Limited (GBL), through its clinical-stage biotech division Sathgen Therapeutics, has secured a Chinese patent for its novel anti-cancer molecule, HYDROXY-1,4-NAPHTHALENEDIONE. This development strengthens India’s footprint in global biotechnology innovation and highlights GBL’s growing role in oncology drug research.

The patent, granted by the China National Intellectual Property Administration (CNIPA), covers a new class of compounds that have shown strong inhibitory effects on cancer and cancer stem cells in laboratory studies. In-vitro results have demonstrated high efficacy against multiple cancer types, including breast and prostate cancer.

Dr Sangeeta Srivastava, Executive Director of GBL, stated, “Our focus on original, high-quality science continues to guide our journey beyond green chemistry into life sciences. This Chinese patent reinforces the promise of our lead molecule and the vital work being done by our team at Sathgen Therapeutics to develop innovative therapies for some of the most pressing medical needs worldwide.”

Driving global research from India

Sathgen Therapeutics, the biotech arm of Godavari Biorefineries, is leading research in cancer and antiviral therapies. With its lead molecule currently undergoing clinical trials, the company is pushing the boundaries of translational medicine — moving promising compounds from lab to clinic.

The Chinese patent will expand the company’s global IP portfolio, allowing it to explore commercialisation avenues, licensing opportunities, and collaborations in international markets.

Innovative research with international relevance

With this milestone, GBL affirms its ability to deliver world-class innovation from India. The molecule HYDROXY-1,4-NAPHTHALENEDIONE marks a strategic shift from traditional green chemistry to high-impact clinical research.

The company already exports to over 20 countries and maintains strong ties with international R&D networks. This patent not only secures intellectual property in a major global market but also lays the groundwork for future breakthroughs.

About Godavari Biorefineries

Godavari Biorefineries Limited (GBL) is a pioneer in renewable chemicals and biofuels, and is now emerging as a key player in life sciences and biotech. Listed on the BSE (544279) and NSE (GODAVARIB), the company is focused on sustainability and scientific innovation.

Its biotech division, Sathgen Therapeutics, is working on developing novel cancer therapies, with an emphasis on compounds that offer targeted treatment and fewer side effects.

With this Chinese patent win, GBL takes a major step forward in its journey to become a globally recognised

The Upcoming IPOs in this week and coming weeks are Sellowrap Industries, Repono, Shanti Gold International, Indiqube Spaces, GNG Electronics, Brigade Hotel Ventures, Patel Chem Specialities, TSC India, NSDL.

The Current active IPO are Monarch Surveyors & Engineering Consultants, Swastika Castal, Savy Infra.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.